Journal
CELL METABOLISM
Volume 33, Issue 6, Pages 1234-+Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2021.03.024
Keywords
-
Categories
Funding
- National Institutes of Health [R01DK102572]
- PKD Foundation Research Grant Award
- PKD Foundation Research Fellowship
- O'Brien Kidney Research Core Center at UT Southwestern Medical Center (UTSW) [P30DK079328]
- National Institutes of Health/NIDDK [U54 DK126126]
Ask authors/readers for more resources
Mettl3 and m(6)A levels are increased in ADPKD, and Mettl3 deletion slows cyst growth, while methionine and SAM are associated with ADPKD development. Furthermore, Mettl3 activates cyst-promoting pathways in ADPKD through epitranscriptional modifications.
Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic disorder marked by numerous progressively enlarging kidney cysts. Mettl3, a methyltransferase that catalyzes the abundant N-6-methyladenosine (m(6)A) RNA modification, is implicated in development, but its role in most diseases is unknown. Here, we show that Mettl3 and m(6)A levels are increased in mouse and human ADPKD samples and that kidney-specific transgenic Mettl3 expression produces tubular cysts. Conversely, Mettl3 deletion in three orthologous ADPKD mouse models slows cyst growth. Interestingly, methionine and S-adenosylmethionine (SAM) levels are also elevated in ADPKD models. Moreover, methionine and SAM induce Mettl3 expression and aggravate ex vivo cyst growth, whereas dietary methionine restriction attenuates mouse ADPKD. Finally, Mettl3 activates the cyst-promoting c-Myc and cAMP pathways through enhanced c-Myc and Avpr2 mRNA m(6)A modification and translation. Thus, Mettl3 promotes ADPKD and links methionine utilization to epitranscriptomic activation of proliferation and cyst growth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available